Submitted by Maike Costa (maiksebas@gmail.com) on 2016-03-17T14:18:06Z No. of bitstreams: 1 arquivo total.pdf: 7513178 bytes, checksum: 415256159369a9e32c9dd78249499c7a (MD5) / Made available in DSpace on 2016-03-17T14:18:06Z (GMT). No. of bitstreams: 1 arquivo total.pdf: 7513178 bytes, checksum: 415256159369a9e32c9dd78249499c7a (MD5) Previous issue date: 2016-05-22 / não possui resumo / não possui resumo

Les sphingolipides et plus particulièrement les bases à longue chaîne (LCBs) jouent un rôle crucial dans l'induction de la mort cellulaire programmée. Chez les végétaux, la fumonisine B1 (FB1), une mycotoxine produite par le champignon nécrotrophe Fusarium moniliforme, perturbe la voie de biosynthèse des sphingolipides ce qui conduit à l'accumulation des deux LCBs majoritaires chez Arabidopsis thaliana, à savoir la phytosphingosine (PHS) et la dihydrosphingosine (DHS). Néanmoins, la voie de signalisation induite par la FB1 demeure largement inconnue à ce jour. En utilisant A. thaliana, l'équipe a récemment montré qu'en réponse aux LCBs ou à la FB1, les protéines 14-3-3 sont phosphorylées par la protéine kinase dépendante du calcium CPK3, à laquelle elles sont associées de manière constitutive. Cette phosphorylation conduit à la dissociation du complexe CPK3/14-3-3s et au clivage de la protéine kinase qui a été identifiée comme étant un régulateur majeur de cette voie de signalisation. L'objectif de mon travail de thèse s'est inscrit dans la continuité de ces travaux et a consisté, de manière générale, à une meilleure compréhension des processus impliquant la protéine kinase CPK3, notamment sa régulation par les 14-3-3s et son devenir après la dissociation du complexe en réponse aux LCBs. A travers mes travaux de thèse, j'ai pu montrer que CPK3 interagit préférentiellement avec les isoformes de 14-3-3s appartenant au groupe non-epsilon de manière phospho- et calcium-dépendante en condition contrôle. Suite à sa perte d'interaction avec les 14-3-3s, j'ai montré que le domaine variable N-terminal de CPK3 est clivé de manière LCB-dépendante. Ce clivage est à corréler avec l'activation, dépendante de la PHS et de la FB1, de la protéase à cystéine de type papaïne, RD21 (responsive-to-dessication 21). De manière intéressante, alors que la forme pleine longueur de CPK3 est principalement associée aux membranes en condition contrôle, la forme clivée de cette protéine kinase est retrouvée exclusivement au niveau de la fraction soluble. Une approche génétique associée à des analyses phénotypiques indique que RD21 agit en tant que régulateur négatif de la PCD induite par la FB1 chez A. thaliana. / The sphingolipids and more particularly the long chain bases (LCBs) play a crucial role in the induction of programmed cell death. In plants, the mycotoxin fumonisin B1 (FB1) produced by the necrotrophic fungus Fusarium moniliforme disrupts sphingolipid biosynthesis, leading to the accumulation of the two major LCBs in Arabidopsis thaliana, i.e. phytosphingosine (PHS) and dihydrosphingosine (DHS). However, the FB1-induced signaling pathway remains largely unknown. By using A. thaliana as a plant model, the team has recently shown that, upon LCB or FB1 treatment, 14-3-3 proteins are phosphorylated by the calcium-dependent protein kinase, CPK3, with which 14-3-3s are constitutively associated. This phosphorylation event leads to the dissociation of the CPK3/14-3-3 complex and to CPK3 cleavage, which was identified as a crucial regulator of this signaling pathway. In this context, the objectives of my thesis were to get a deep further in the knowledge of this signaling pathway involving the protein kinase CPK3, including its regulation by 14-3-3s and its becoming after complex dissociation in response to LCBs. Thus, I have shown that CPK3 preferentially binds to the non-epsilon 14-3-3 isoforms in a phospho- and calcium-dependent manner in control condition. After the CPK3/14-3-3 complex dissociation, I have demonstrated that the N-terminal variable domain of CPK3 is cleaved in a LCB-dependent manner. This cleavage can be correlated with the PHS/FB1-induced activation of the papain-like cysteine protease, RD21 (responsive-to-dessication 21). Interestingly, while full-length CPK3 is mainly associated to membranes in control condition, its FB1-induced cleaved form becomes soluble. A genetic approach associated to phenotype analyses indicates that RD21 acts as a negative regulator of FB1-induced cell death in A. thaliana.

Both p130Cas and PKN3 are important regulators of cellular signaling deregulation of which leads to malignant behavior of cancer cells. Recently we have found that SH3 domain of p130Cas mediates interaction with proline rich region of PKN3 suggesting their possible cooperation in regulation of these processes. In this work we have focused on the phosphorylation of p130Cas by PKN3 and identified serine 498 (S498) within the serine rich domain of p130Cas to be phosphorylated by PKN3 in vitro. Given that S498 is localized within the 14-3-3 binding motif and its phosphorylation is required for interaction of p130Cas with 14-3-3 proteins, we propose potential existence of novel PKN3/p130Cas/14-3-3 signaling axis. In the second part of the work we have studied this pathway in response to antiestrogen treatment in estrogen receptor positive breast cancer cell line MCF7. Although we have shown inactivation of PKN3 occurs as an early response to tamoxifen treatment, we do not rule out its possible role in further promotion of resistance to antiestrogens. Furthermore, understanding the signaling triggered by interaction of PKN3 with p130Cas and its possible downstream effects on promoting malignant growth of cancer cells would help in finding novel therapeutic targets.

While a relatively limited number of known oncogenes underlie a large percentage of cancers, a variety of new genes have emerged as low-frequency cancer drivers. Each of these new oncogenes represents a frontier for targeted therapy. However, the discovery of low-frequency targetable oncogenic drivers is challenging. This study focuses on the poorly understood Tyrosine kinase non-receptor-1 (TNK1), which has been reported to have both oncogenic and tumor suppressive functions. TNK1 has been identified to promote cancer cells survival and promote chemoresistance in multiple independent studies. On the other hand, whole-body constitutive deletion of TNK1 in mice caused an increase in spontaneous carcinomas and lymphomas. All in all, with no known regulatory mechanism and substrates of TNK1, the precise biological role of TNK1 is still unclear. To understand how TNK1 is regulated, we employed a proteomic approach to identify TNK1 interactors. We found out that TNK1 interacts with the phospho-binding protein 14-3-3 and this interaction is mediated by a cluster of MARK-mediated phosphorylations within the proline-rich domain. 14-3-3 binding retains TNK1 in the cytosol and maintains TNK1 in an inactive state. Release of TNK1 from 14-3-3 binding drives TNK1 to a heavy membrane fraction, where it becomes highly active. One unique feature of TNK1 is an ubiquitin association domain (UBA) on its C-terminus. Our data suggest that the UBA domain of TNK1 binds to poly-ubiquitin chains in nondiscriminatory manner. Remarkably, point mutations within the UBA that disrupt ubiquitin binding abolish TNK1 activation and oncogenic signaling, suggesting, to our knowledge, a unique UBA-centric mechanism of tyrosine kinase regulation. Finally, we used a structure-guided approach to identify a small molecule inhibiting TNK1 with high potency and selectivity. Such compound, TP-5801, inhibits TNK1 dependent STAT3 phosphorylation. TP-5801 also prolongs the survival of mice injected via tail vein with TNK1-driven Ba/F3 cells and reduces tumor burden in a subcutaneous xenograft model. In conclusion, our data reveal a mechanism of TNK1 regulation that controls its oncogenic tyrosine kinase activity and a potential strategy for TNK1 inhibition.

No description available.

A novel small molecule, 1-ethoxy-3-(3,4-methylenedioxyphenyl)-2-propanol (EOD), was synthesized in our laboratory. Previously, we reported pharmacological properties of EOD, triggering apoptosis in Human umbilical vein endothelial cells (HUVECs). Here, we further investigated the effects of EOD on the growth of A549 human lung cancer cells. EOD treatment induced apoptosis in A549 cells via up-regulating the expression of P53 protein, blocking cell cycle partly at G1 phase, and ultimately activating caspase-3. In contrast, caspase-8 might be irrelevant to EOD-triggered apoptosis. This study indicated that EOD might be a potential chemopreventive agent for lung cancer. The work would encourage us to add more novel compounds to our 'library' of small molecules derived through modern synthetic organic chemistry, and would drive us to determine the proteins that the compounds target.

Indiana University-Purdue University Indianapolis (IUPUI) / Misregulation of protein signaling pathways is the basis for many human diseases, and thus 95% of Food and Drug Administration approved drugs target proteins. Proteins are dynamic entities which can undergo transitions to reach different conformational states. The conformational state of a protein, or its three-dimensional shape, is intricately linked to functions, such as association with endogenous or exogenous binding partners, or catalysis. Thus, it is of interest to the pharmacological community to understand the mechanisms of protein conformational state transitions in order to better target and control protein functions. In two case studies, I show the importance of understanding protein dynamics in protein function and drug design. In the case of human immunodeficiency virus-1 (HIV-1) protease, a tremendous “open-and-closed” conformational transition is revealed by Molecular Dynamics Simulations (MDS). Through observing the dramatic difference in effectiveness of two Darunavir inhibitor derivatives differentiated by a single atom at locking the protease in the closed conformation, we discovered the residues and mechanism that lead to the protease’s conformational transition. This mechanism also explained the significant difference in the binding conformation and binding affinity of these two inhibitors. This study provides insight on how to improve the potency and anti-viral capacity of these compounds. In the second case study, MDS enabled us to observe the conformational transitions of a family of seven isoforms known as the 14-3-3 proteins. Many vital cellular processes involve all or select 14-3-3 isoforms, making this family very difficult to target. Through MDS, I discovered different conformational samplings among these 14-3-3 isoforms which were then validated by SAXS. Subsequently, a FRET-based ligand binding assay was developed which can screen for preferential 14-3-3 isoform binding of endogenous ligands, giving hope that using conformations unique to a 14-3-3 isoform of interest can provide a method for selective drug design. / 2022-03-09

Prostate tumor overexpressed 1 (PTOV1) is highly expressed in several forms of cancer. High expression of PTOV1 is associated with tumor aggressiveness in several tumor types, including ovarian and breast cancer. Currently, PTOV1 is known to act both as a translational and transcriptional regulator aiding in the expression of prosurvival genes. Although PTOV1 is known to pass in and out of the nucleus in a cell cycle-dependent manner, the regulation of PTOV1 activity is not well understood and here we identify 14-3-3 as a PTOV1 interactor and show that high levels of 14-3-3 expression, like PTOV1, correlate with prostate cancer progression. Further, we identify SGK2-mediated phosphorylation at S36 of PTOV1 that is required for 14-3-3 binding. Disruption of the PTOV1-14-3-3 interaction results in an accumulation of PTOV1 in the nucleus and a proteasome-dependent reduction in PTOV1 protein levels, which requires ubiquitination at K114 of PTOV1. We also observed HUWE1 as a PTOV1-interacting partner responsible for the degradation of PTOV1 through the proteasome. We show that loss of 14-3-3 binding leads to an increase in PTOV1-HUWE1 binding, suggesting that 14-3-3 stabilizes PTOV1 protein by sequestering PTOV1 in the cytosol and inhibiting its interaction with HUWE1. Finally, our data suggest that stabilization of the 14-3-3-bound form of PTOV1 promotes PTOV1-mediated expression of cJun. Together, these data support a model that explains how 14-3-3 and HUWE1 regulate the PTOV1 stability, localization, and function within the cell.

14-3-3 proteins are among a family of phospho-binding proteins that are known to regulate many essential cellular mechanisms. By binding to sites of phosphorylation, 14-3-3s are integrated into multiple signaling pathways that govern critical processes, such as apoptosis, cell cycle progression, autophagy, glucose metabolism, and cell motility. These processes are crucial for tumorigenesis and 14-3-3 proteins are known to play a central role in facilitating cancer progression. In this study, my colleagues and I discover two novel 14-3-3 interacting proteins, ATG9A and PTOV1, that are both vital to essential cellular functions and describe various mechanisms that these two proteins regulate. ATG9A is a multi-pass transmembrane lipid scramblase that is found primarily as a homotrimer in the ER or small ATG9A vesicles. It is essential in the cellular recycling process called autophagy and is believed to act at the earliest stages of autophagy by providing the seed for the growth of the double membrane vesicle called an autophagosome. Previous work in our lab demonstrated that upon hypoxic stress, AMPK, the master nutrient-sensing kinase, phosphorylates S761 on the C-terminus of ATG9A. This triggers the binding of 14-3-3ζ to contribute to ATG9A function in hypoxia induced autophagy. Despite this revelation, the exact function of ATG9A is still poorly understood, especially in unstimulated conditions where autophagy functions at a basal level and AMPK is inactive. In this study, we sought to understand ATG9A function more broadly by identifying novel interactors of ATG9A and the role ATG9A plays in basal autophagy. To do this, we employed BioID mass spectrometry and various biochemical approaches to identify LRBA as a bona fide ATG9A interactor and autophagy regulator. Furthermore, using deuterium labeling and quantitative whole proteome mass spectrometry, and various other biochemical techniques, we show that ATG9A regulates the basal degradation of p62 and is recruited to sites of basal autophagy by active poly-ubiquitination to initiate basal autophagy. PTOV1 is an oncogenic protein that is poorly understood. Our current understanding of PTOV1 is limited to a few studies, which demonstrate that PTOV1 is highly expressed in primary prostate tumor samples and is correlated with metastasis, drug resistance, and poor clinical outcomes. In this study, we identify a mechanism by which SGK2, a poorly understood kinase, phosphorylates PTOV1 at S36 to trigger 14-3-3 binding at that site to increase PTOV1 stability in the cytosol and increase c-Jun expression. Upon SGK2 inhibition, 14-3-3 releases PTOV1 and PTOV1 is shuttled into the nucleus where HUWE1, an E3 ubiquitin ligase, ubiquitinates PTOV1 and initiates PTOV1 degradation by the proteasome. This is the first detailed mechanism of regulation identified for the poorly understood oncogene, PTOV1, and sheds light on potential therapeutic targets for cancer treatments.

No description available.